哌罗匹隆与利培酮治疗女性首发精神分裂症对照研究  

A control study of perospirone vs. risperidone in the treatment of female first-episode schizophrenia

作　　者：岳红卫[1] 方敏[1] 马利敏[1] 

机构地区：[1]焦作煤业集团中央医院三分院,河南·焦作454173

出　　处：《临床心身疾病杂志》2016年第5期35-37,共3页Journal of Clinical Psychosomatic Diseases

摘　　要：目的探讨哌罗匹隆与利培酮治疗女性首发精神分裂症的临床疗效和安全性。方法将96例女性首发精神分裂症患者按随机数字表法分为观察组和对照组，每组48例，观察组口服哌罗匹隆治疗，对照组口服利培酮治疗，观察2个月。治疗前后采用阳性与阴性症状量表评定临床疗效，随时记录治疗过程中出现的不良反应。结果治疗后两组阳性与阴性症状量表评分均较治疗前呈持续性下降（P〈0．01），治疗2个月观察组总有效率为87．5％、对照组为85．4％，两组总有效率比较差异无显著性（P〉0．05）。两组不良反应较轻微，但观察组月经紊乱、体质量增加、锥体外系反应发生率显著低于对照组（P〈0．05或0．01）。结论哌罗匹隆与利培酮治疗女性首发精神分裂症疗效显著，安全性高，但哌罗匹隆较少引起月经改变、体质量增加及锥体外系不良反应，尤其适用于女性首发精神分裂症患者。Objective To explore the efficacy and safety of perospirone and risperidone in the treatment of female first-episode schizophrenia. Methods Ninety-six female first-episode schizophrenics were randomly assigned to observation and control group of 48 ones each, observation group took orally perospirone and control did risperidone for 2 months. Efficacies were assessed with the Positive and Negative Syndrome Scale （PANSS） before and after treatment and adverse reactions were recorded at any time during treatment. Results After treatment the PANSS scores of both groups continuously lowered compared with pretreatment （P〈0.01）, after 2 month treatment total effective rate was respectively 87.5% in observation and 85.4% in control group, which showed no significant group difference （P〉0.05）. Adverse reactions of both groups were mild, but the incidences of menstrual disorder, weight gain and extrapyramidal side effects were significantly lower in observation than control group （P〈0.05 or 0.01）. Conclusion Perospirone and risperidone are effective and safe in the treatment of female first-episode schizophrenia, but perospirone less causes such adverse reactions as menstrual disorder, weight gain and extrapyramidal side effects and is more suitable for female first-episode schizophrenia.

关 键 词：首发精神分裂症 女性 哌罗匹隆 利培酮 阳性与阴性症状量表 临床疗效 不良反应 

分 类 号：R749.3[医药卫生—神经病学与精神病学]